Phase 3 trial shows overall survival benefit from adjuvant therapy in kidney cancer patients

  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 41 sec. here
  • 17 min. at publisher
  • 📊 Quality Score:
  • News: 72%
  • Publisher: 71%

Cancer News

Immunotherapy,Kidney,Kidney Cancer

For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer.

Apr 17 2024Dana-Farber Cancer Institute

The KEYNOTE-564 trial was designed to evaluate adjuvant pembrolizumab following nephrectomy within 12 weeks prior to randomization. The double-blind, phase 3 study, carried out at hundreds of sites internationally, enrolled 994 patients who were randomized to pembrolizumab once every three weeks for about a year, or a placebo. Pembrolizumab targets a molecular pathway that cancer cells commandeer to evade attack by the body's immune system.

Related Stories"Since 1973, more than 12,000 patients with kidney cancer participated in adjuvant studies versus a control arm and none of the studies showed the experimental arm extends lives until now with the KEYNOTE-564 study," says Choueiri. "We showed pembrolizumab extends survival. It doesn't only delay recurrence."

Immunotherapy Kidney Kidney Cancer Surgery Adjuvant Therapy Carcinoma Cell Children Hospital Immune System Medicine Nephrectomy Oncology Placebo Research

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 19. in UK

United Kingdom Latest News, United Kingdom Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Saruparib demonstrates early efficacy in breast cancers with DNA repair defects in Phase I/II trialThe first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results from the Phase I/II PETRA trial led by researchers at The University of Texas MD Anderson Cancer Center.
Source: medical_xpress - 🏆 101. / 51 Read more »

Telegraph acquisition may 'operate against the public interest', Ofcom says, as investigation enters phase 2Regulatory approval may be a moot point as the government last week announced plans to ban foreign governments from owning British newspapers - effectively blocking the deal.
Source: SkyNews - 🏆 35. / 67 Read more »

Biden administration announces climate rules to phase out gas carsThe rules come as sales of electric vehicles, which are needed to meet the standards, have begun to slow.
Source: DailyMailUK - 🏆 7. / 90 Read more »

First phase of investment to improve Glasgow railway bridges completedThe first phase of work to improve three Glasgow railway bridges has been completed following a big investment.
Source: Glasgow_Times - 🏆 76. / 59 Read more »

Next Phase of Covid-19 Vaccination Programme BeginsThe NHS is starting the next phase of the Covid-19 vaccination programme, targeting those whose immunity may have waned since their last shot. This phase includes everyone over 75, care home residents, and the immunosuppressed. Housebound patients and care home residents will be among the first to receive their top-up jabs.
Source: LiveLancs - 🏆 10. / 87 Read more »

Three early-phase clinical studies show promising initial data for patients with lymphoma, gastric cancersThree early-phase clinical studies presented by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2024 show promising initial data for patients with lymphoma, gastric or gastroesophageal junction cancers, and specific molecularly selected tumors.
Source: NewsMedical - 🏆 19. / 71 Read more »